Presenter: Mina Lobbous, MBChB, MD, MSPH, University of Alabama at Birmingham
Session Name: Central Nervous System Tumors
Date and Time: Saturday, June 1, 2024 from 10:00 a.m. 1:00 p.m. EDT
Poster Board: #341
The poster
presentation is accessible on the Companys website here.
About INB-200
INB-200 is a genetically modified autologous DeltEx DRI product candidate for the treatment of solid tumors. This novel
platform utilizes genetic engineering to generate chemotherapy-resistant gamma delta T cells which can be administered concurrently with standard-of-care treatment in
solid tumors. This is a powerful, synergistic investigational treatment approach designed to enable gamma-delta T cells to persist in the presence of chemotherapy and maintain their natural ability to recognize, engage and kill cancer cells.
INB-200 is the first genetically engineered gamma-delta T cell therapy to be administered to patients with solid
tumors in an initial indication of GBM.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for
solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bios DeltEx platform employs allogeneic,
autologous, iPSC and genetically modified approaches to develop cell therapies designed to effectively identify and eradicate tumor cells.
IN8bio has
initiated a Phase 2 trial of INB-400 in GBM at multiple centers across the United States and has two ongoing Phase 1 trials in solid and hematological tumors, including
INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. IN8bio also has a broad portfolio of preclinical programs focused on
addressing other hematological and solid tumor cancers. For more information about IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking Statements
This press release may
contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as aims, anticipates,
believes, could, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks,
will and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release
include, but are not limited to, statements regarding the potential of IN8bios product candidates therapeutic potential; the potential of DeltEx DRI to treat patients with newly